Article Information
History
- June 3, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Martin J. Scurr1,2,
- Wioleta M. Zelek3,4,
- George Lippiatt2,
- Michelle Somerville1,
- Stephanie E. A. Burnell1,
- Lorenzo Capitani1,
- Kate Davies5,
- Helen Lawton5,
- Thomas Tozer6,
- Tara Rees6,
- Kerry Roberts6,
- Mererid Evans7,
- Amanda Jackson7,
- Charlotte Young7,
- Lucy Fairclough8,
- Mark Wills9,
- Andrew D. Westwell10,
- B. Paul Morgan3,4,
- Awen Gallimore*,1,3,§ and
- Andrew Godkin*,1,3,6,§
- 1Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK
- 2ImmunoServ Ltd., Cardiff, UK
- 3Systems Immunity University Research Institute, School of Medicine, Cardiff University, Cardiff, UK
- 4UK Dementia Research Institute Cardiff, Cardiff University, Cardiff, UK
- 5Radyr Medical Centre, Cardiff, UK
- 6Dept. of Gastroenterology & Hepatology, University Hospital of Wales, Heath Park, Cardiff, UK
- 7Velindre Cancer Centre, Cardiff, UK
- 8School of Life Sciences, University of Nottingham, Nottingham, UK
- 9Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, UK
- 10School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
- ↵*Corresponding Authors: Prof Andrew Godkin, Division of Infection and Immunity, Henry Wellcome Building, Health Park, Cardiff, CF14 4XN, Email: godkinaj{at}cardiff.ac.uk
Posted June 03, 2021.
Whole blood-based measurement of SARS-CoV-2-specific T cell responses reveals asymptomatic infection and vaccine efficacy in healthy subjects and patients with solid organ cancers
